| Autor: |
Günzel, K., Magheli, A., Baco, E., Cash, H., Heinrich, S., Neubert, H., Schlegel, J., Schostak, M., Henkel, T., Asbach, P., Hinz, S. |
| Předmět: |
|
| Zdroj: |
World Journal of Urology; Oct2021, Vol. 39 Issue 10, p3861-3866, 6p |
| Abstrakt: |
Purpose: The aim of this study was to assess the post biopsy infection rate, feasibility and prostate cancer (PCa) detection rate (CDR) by performing transperineal MRI-TRUS fusion biopsy of the prostate (TPBx) under local anesthesia (LA) without antibiotic prophylaxis (AP). Methods: We prospectively screened 766 men with suspicious lesions on mpMRI, an elevated PSA level or a suspect digital examination undergoing MRI-TRUS-TPBx in LA, from May 2019 to July 2020. Patients with the need for antibiotic prophylaxis or without a PI-RADS target lesion were excluded from final analyses. We reported CDR, perioperative pain (0–10) and postoperative complications. PCa with an ISUP grade ≥ 2 was classified as clinically significant PCa (csPCa). Results: We included 621 patients with a median age of 68 years (IQR 62–74), a PSA of 6.43 ng/mL (IQR 4.72–9.91) and a prostate volume of 45 cc (IQR 32–64). In median, 4 targeted (TB) (IQR 3–4) and 6 (IQR 5–7) systematic biopsies (SB) detected in combination overall 416 (67%) PCa and 324 (52%) csPCa. Overall CDR of TB for PI-RADS 3, 4 and 5 was 26%, 65% and 84%, respectively. Patients reported a median perioperative pain level of 2 (IQR 1–3). Four patients (0.6%) developed a post biopsy infection, one experienced urosepsis. Conclusion: Our results demonstrate that transperineal MRI-TRUS fusion-guided prostate biopsy under LA without AP is feasible, safe and well tolerated. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink